These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 23806241

  • 1. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 2. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 4. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 5. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.
    Vaccine; 2011 Nov 08; 29(48):8929-36. PubMed ID: 21945961
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M.
    Eur J Cancer; 2011 Feb 08; 47(3):428-35. PubMed ID: 20971633
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N.
    Vaccine; 2014 May 07; 32(22):2645-56. PubMed ID: 24662710
    [Abstract] [Full Text] [Related]

  • 13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L, Joura E, Largeron N, Prager B, Uhart M.
    BMC Infect Dis; 2016 Apr 16; 16():153. PubMed ID: 27084683
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP.
    J Manag Care Pharm; 2010 Apr 07; 16(3):217-30. PubMed ID: 20331326
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
    Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ.
    Expert Rev Vaccines; 2015 Apr 07; 14(4):589-604. PubMed ID: 25482311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.